While DLL3-targeted therapies show particular promise in tumors with high antigen homogeneity like SCLC, their clinical application in other cancers requires careful consideration of tumor microenvironment complexities, blood-brain barrier limitations, and compensatory signaling pathways. This evidence concerns the gene DLL3 and cancer.